Andere Sprachen Tempest Therapeutics, Inc.

Aktien

A3CSM8

US87978U1088

TPST

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:10:30 01.05.2024			% 5 Tage	% 1. Jan.
3.485 ^USD	+0.43%		+1.19%	-20.89%

09.04.	Tempest Therapeutics, Inc. berichtet auf der AACR-Jahrestagung neue präklinische Daten für TPST-1120 bei RCC	CI
04.04.	Tempest Therapeutics, Inc. gibt die Veröffentlichung positiver Daten aus der Phase-1-Studie mit TPST-1120 bei Patienten mit fortgeschrittenen soliden Tumoren im Journal of Cancer Research Communications bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	26.04.
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	10.04.
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	09.04.
Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	09.04.
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04.04.
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04.04.
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04.04.
Tempest Therapeutics : Corporate Presentation - April 2024	29.03.
Tempest Therapeutics : Corporate Presentation - March 2024	22.03.
Tempest Reports Year End 2023 Financial Results and Provides Business Update	20.03.
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
Tempest Reports Year End 2023 Financial Results and Provides Business Update	19.03.
Tempest Therapeutics : Reports Year End 2023 Financial Results and Provides Business Update - Form 8-K	19.03.
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)	14.03.
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	12.03.
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	12.03.
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types	12.03.
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting	05.03.
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	26.02.
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tempest Therapeutics, Inc.

Aktien

A3CSM8

US87978U1088

TPST

Andere Sprachen

Filter